Olaparib (Lynparza, AstraZeneca) is indicated for 'the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy'.
The dosage schedule is available in the summary of product characteristics for olaparib.
The list price for olaparib is £2,317.50 (56 x 150 mg tablets) per 14‑day pack and £4,635.00 per 28‑day cycle (excluding VAT; BNF online accessed January 2024).
The company has a commercial arrangement. This makes olaparib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.